首页 > 最新文献

I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]最新文献

英文 中文
[Parenchyma sparing: evolution of the resective surgical approach of hepatic metastasis from the colorectum]. [保留实质:结肠直肠肝转移手术入路的演变]。
L Viganò, A Ferrero, E Sgotto, R Polastri, A Muratore, L Capussotti

Liver surgery for colorectal metastasis has moved toward a parenchymal sparing strategy in order to reduce postoperative liver failure, to resect an higher number of metastases and to allow a future re-resection. Patients undergone hepatectomy in our Department before and after 1999 were retrospectively compared. In the recent years surgery became more aggressive: a higher number of patients with multiple and bilateral lesions were treated. Short-term results improved in the recent series. After 1999, the rate of wedge resections was significantly increased with the same oncological radicality and with improved long-term results. Moreover, parenchymal sparing strategy allowed a higher re-resection rate in patients with liver recurrence.

为了减少术后肝衰竭,切除更多的转移瘤,并允许将来再次切除,结肠转移的肝脏手术已转向保留实质策略。对1999年前后我科行肝切除术的患者进行回顾性比较。近年来,手术变得更加激进:更多的患者接受了多发性和双侧病变的治疗。最近一系列的短期业绩有所改善。1999年后,楔形切除率显著增加,肿瘤根治性相同,长期疗效也有所改善。此外,肝实质保留策略允许肝复发患者更高的再切除率。
{"title":"[Parenchyma sparing: evolution of the resective surgical approach of hepatic metastasis from the colorectum].","authors":"L Viganò,&nbsp;A Ferrero,&nbsp;E Sgotto,&nbsp;R Polastri,&nbsp;A Muratore,&nbsp;L Capussotti","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Liver surgery for colorectal metastasis has moved toward a parenchymal sparing strategy in order to reduce postoperative liver failure, to resect an higher number of metastases and to allow a future re-resection. Patients undergone hepatectomy in our Department before and after 1999 were retrospectively compared. In the recent years surgery became more aggressive: a higher number of patients with multiple and bilateral lesions were treated. Short-term results improved in the recent series. After 1999, the rate of wedge resections was significantly increased with the same oncological radicality and with improved long-term results. Moreover, parenchymal sparing strategy allowed a higher re-resection rate in patients with liver recurrence.</p>","PeriodicalId":84869,"journal":{"name":"I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]","volume":"4 3","pages":"S35"},"PeriodicalIF":0.0,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25821053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Gastrointestinal stromal tumors]. [胃肠道间质瘤]。
C Eccher, R Famà, G Berlanda, M Silvestri, C Prezzi

Gastrointestinal stromal tumors (GIST) are generally found in the stomach or small intestine and less commonly in the colon or rectum. Complete surgical removal remains the best current therapy for GISTs. The treatment of advanced GIST patients is with imatinib, a selective tyrosine kinase inhibitor. In our series, 23 patients observed between 1994 and 2004 and affected by GIST were treated with complete negative margin resections (three cases by laparoscopy).

胃肠道间质瘤(GIST)通常在胃或小肠中发现,在结肠或直肠中较少见。完全手术切除仍然是目前治疗胃肠道间质瘤的最佳方法。晚期GIST患者的治疗是伊马替尼,一种选择性酪氨酸激酶抑制剂。在我们的研究中,在1994年至2004年期间观察到的23例GIST患者接受了完全阴性切缘手术(其中3例通过腹腔镜手术)。
{"title":"[Gastrointestinal stromal tumors].","authors":"C Eccher,&nbsp;R Famà,&nbsp;G Berlanda,&nbsp;M Silvestri,&nbsp;C Prezzi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Gastrointestinal stromal tumors (GIST) are generally found in the stomach or small intestine and less commonly in the colon or rectum. Complete surgical removal remains the best current therapy for GISTs. The treatment of advanced GIST patients is with imatinib, a selective tyrosine kinase inhibitor. In our series, 23 patients observed between 1994 and 2004 and affected by GIST were treated with complete negative margin resections (three cases by laparoscopy).</p>","PeriodicalId":84869,"journal":{"name":"I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]","volume":"4 3","pages":"S102-3"},"PeriodicalIF":0.0,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25821058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pancreatic insulinomas: diagnosis and surgical treatment of 45 patients. 45例胰腺胰岛素瘤的诊断与手术治疗。
R Caronna, G Tamburrano, F Leonetti, M Cardi, A Bonifacino, S Mangioni, S Corelli, F Priore, E Benvenuti, M Marengo, D Layec, V Stipa, P Chirletti
{"title":"Pancreatic insulinomas: diagnosis and surgical treatment of 45 patients.","authors":"R Caronna,&nbsp;G Tamburrano,&nbsp;F Leonetti,&nbsp;M Cardi,&nbsp;A Bonifacino,&nbsp;S Mangioni,&nbsp;S Corelli,&nbsp;F Priore,&nbsp;E Benvenuti,&nbsp;M Marengo,&nbsp;D Layec,&nbsp;V Stipa,&nbsp;P Chirletti","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":84869,"journal":{"name":"I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]","volume":"4 3","pages":"S65-7"},"PeriodicalIF":0.0,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25822105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical case: multiple synchronous and metachronous cancer]. 【临床病例:多发同步异时性癌】。
N Di Martino, G Izzo, A Cosenza, A Renzi, L Vicenzo, L Monaco, F Torelli, A Basciotti, A Brillantino
{"title":"[Clinical case: multiple synchronous and metachronous cancer].","authors":"N Di Martino,&nbsp;G Izzo,&nbsp;A Cosenza,&nbsp;A Renzi,&nbsp;L Vicenzo,&nbsp;L Monaco,&nbsp;F Torelli,&nbsp;A Basciotti,&nbsp;A Brillantino","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":84869,"journal":{"name":"I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]","volume":"4 3","pages":"S216"},"PeriodicalIF":0.0,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25822394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Intraperitoneal hyperthermic chemotherapy. Preliminary experience with 22 consecutive patients]. 腹腔热化疗。22例连续患者的初步经验]。
V Ceriani, P Bignami, E Faleschini, T Lodi, O Roncaglia, C Osio, D Sarli

The study analyses the results of surgical treatment and intraperitoneal hyperthermic chemotherapy on a group of 22 patients, affected by peritoneal carcinomatosis of different origins, and treated at Policlinico Multimedica (Milan) between June 2001 and December 2004. Surgical major complications were present in the 23% of the patients, and post-operative mortality rate was 13%. None of the patients presented chemotherapy related toxicity. Six patients died within 2 and 40 months after surgery, while 13 are alive within 4 and 40 months after operation.

本研究分析了2001年6月至2004年12月在米兰polilinico Multimedica医院治疗的22例不同来源的腹膜癌患者的手术治疗和腹腔热化疗的结果。23%的患者出现手术主要并发症,术后死亡率为13%。所有患者均未出现化疗相关毒性。术后2个月和40个月内死亡6例,术后4个月和40个月内存活13例。
{"title":"[Intraperitoneal hyperthermic chemotherapy. Preliminary experience with 22 consecutive patients].","authors":"V Ceriani,&nbsp;P Bignami,&nbsp;E Faleschini,&nbsp;T Lodi,&nbsp;O Roncaglia,&nbsp;C Osio,&nbsp;D Sarli","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The study analyses the results of surgical treatment and intraperitoneal hyperthermic chemotherapy on a group of 22 patients, affected by peritoneal carcinomatosis of different origins, and treated at Policlinico Multimedica (Milan) between June 2001 and December 2004. Surgical major complications were present in the 23% of the patients, and post-operative mortality rate was 13%. None of the patients presented chemotherapy related toxicity. Six patients died within 2 and 40 months after surgery, while 13 are alive within 4 and 40 months after operation.</p>","PeriodicalId":84869,"journal":{"name":"I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]","volume":"4 3","pages":"S124-5"},"PeriodicalIF":0.0,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25820961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Laparoscopic surgery of adrenal gland metastasis: case report]. [腹腔镜手术治疗肾上腺转移1例]。
M R Balestra, L Napolitano, M Legnini, P Innocenti

Objective: Laparoscopic adrenalectomy is unanimously recognised as the gold standard for the surgical treatment of adrenal lesion. Also the role of laparoscopic adrenalectomy (LA) for metastasis is controversial. This study, in according with literature dates, aimed to confirm that patients are most likely to have prolonged survival after resection of adrenal metastases and confirms that oncological outcome of laparoscopic adrenalectomy are similar with open adrenalectomy.

Patient and methods: The study included patients who underwent LA from 2000 to 2005. Indications for LA were adrenal masses with no radiological evidence of involvement of the surrounding structure, or solitary metastases with well-controlled primary cancer. The variable evaluated were port-site and intra-addominal recurrence, distant metastasis and survival time. Primary tumors were the followings: lymphoma non-Hodgkin, lung cancer. Patients age was mean 69 (range, 62-77), the lesions were at right adrenal gland. No conversion to open surgery occurred. No complication were observed. Mean operative time was 100 minutes (range, 90-110). No postoperative complication occurred. Mean diameter of the tumor was 4.5 cm (range, 4.2-4.8 cm). Tumor free margins were obtained. Mean hospital stay was 3 day. At follow-up mean of ten months (eight-twelve months) there was any sight of distant metastases and the patient was alive.

Conclusion: LA seems to be a feasible option if the principles of oncological surgery are respected. Adrenalectomy for metastasis, with intent to prolong survival, should be offered to patient with favourable tumor biology, such as those with significant DFI.

目的:腹腔镜肾上腺切除术被公认为肾上腺病变手术治疗的金标准。此外,腹腔镜肾上腺切除术(LA)在转移中的作用也存在争议。根据文献资料,本研究旨在证实肾上腺转移瘤切除后患者最有可能延长生存时间,并证实腹腔镜肾上腺切除术与开放式肾上腺切除术的肿瘤预后相似。患者和方法:该研究包括2000年至2005年接受LA的患者。LA的适应症是肾上腺肿块,没有放射学证据表明周围结构受累,或原发性癌症控制良好的孤立转移。评估的变量包括肝口部位和腹腔内复发、远处转移和生存时间。原发肿瘤如下:淋巴瘤、非霍奇金、肺癌。患者平均年龄69岁(62 ~ 77岁),病灶位于右侧肾上腺。未发生转开手术。无并发症发生。平均手术时间100分钟(范围90-110分钟)。无术后并发症发生。肿瘤直径平均4.5 cm(范围4.2 ~ 4.8 cm)。获得无瘤边缘。平均住院时间3天。在平均10个月(8 - 12个月)的随访中,有任何远处转移的迹象,患者存活。结论:如果遵守肿瘤手术原则,LA似乎是一种可行的选择。为了延长生存期,应向肿瘤生物学有利的患者提供肾上腺转移切除术,例如有明显DFI的患者。
{"title":"[Laparoscopic surgery of adrenal gland metastasis: case report].","authors":"M R Balestra,&nbsp;L Napolitano,&nbsp;M Legnini,&nbsp;P Innocenti","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Laparoscopic adrenalectomy is unanimously recognised as the gold standard for the surgical treatment of adrenal lesion. Also the role of laparoscopic adrenalectomy (LA) for metastasis is controversial. This study, in according with literature dates, aimed to confirm that patients are most likely to have prolonged survival after resection of adrenal metastases and confirms that oncological outcome of laparoscopic adrenalectomy are similar with open adrenalectomy.</p><p><strong>Patient and methods: </strong>The study included patients who underwent LA from 2000 to 2005. Indications for LA were adrenal masses with no radiological evidence of involvement of the surrounding structure, or solitary metastases with well-controlled primary cancer. The variable evaluated were port-site and intra-addominal recurrence, distant metastasis and survival time. Primary tumors were the followings: lymphoma non-Hodgkin, lung cancer. Patients age was mean 69 (range, 62-77), the lesions were at right adrenal gland. No conversion to open surgery occurred. No complication were observed. Mean operative time was 100 minutes (range, 90-110). No postoperative complication occurred. Mean diameter of the tumor was 4.5 cm (range, 4.2-4.8 cm). Tumor free margins were obtained. Mean hospital stay was 3 day. At follow-up mean of ten months (eight-twelve months) there was any sight of distant metastases and the patient was alive.</p><p><strong>Conclusion: </strong>LA seems to be a feasible option if the principles of oncological surgery are respected. Adrenalectomy for metastasis, with intent to prolong survival, should be offered to patient with favourable tumor biology, such as those with significant DFI.</p>","PeriodicalId":84869,"journal":{"name":"I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]","volume":"4 3","pages":"S130-1"},"PeriodicalIF":0.0,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25820963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Pelvic recurrence of rectal cancer: our experience]. 【盆腔直肠癌复发:我们的经验】。
N Di Bartolomeo, M R Balestra, G Liddo, P Innocenti

Isolated recurrence of rectal carcinoma have been reported from 7% to 33% with a median of 15. Increasing recurrence is associated with increasing Dukes's stage. Patient who have recurrence after a low-anterior resection are more likely to present with non fixed, surgically correctable lesion versus recurrences after abdominoperineal resection. The most common symptom related to pelvic recurrence is pain, which may be perineal or radiate to the lower extremities. The diagnosis of a locally recurrent rectal cancer was obtained with CT; imaging is the first step to estimate the extent and location of the local tumor growth and the presence or absence of distant metastases. The most common location is at or around the anastomosis and the presacral region. Apart from distant metastases locoregional recurrence is the most important factor determining prognosis and survival. If an R0 resection can be performed, a 5-year survival rate of 20-30% can be achieved. Local or locoregional recurrence implies the reappearance of carcinoma after an intended complete removal of the tumor. For rectal cancer, the adjacent organs include the perineum, bladder and vagina, and LR failure includes perineal or pelvic lesions. Total pelvic exenteration is performed in patients with local recurrence of rectal cancer and a 5-year suvival rate of 30-40% was achieved. For patient with unresectable recurrence, chemotherapy and radiation contribute to a better quality of life and prolong survival. While radiotherapy may reduce recurrence, it is now apparent that total mesorectal excision is the most effective modality, with rates as low as 5%. The anastomotic recurrence that can be locally resected, the best approach for long-term survival is an extensive surgical procedure requiring en bloc removal of adjacent organs and pelvic structures so called composite resection. Intraoperative radiotherapy and brachytherapy, and/or preoperative chemoradiation may provide better results in future. While radioterapy remains the most common antineoplastic modality used for palliation of symptoms, surgical resection remains the mainstay of curative treatment for carcinoma of colon and rectum.

据报道,孤立性直肠癌的复发率从7%到33%,中位数为15%。复发率的增加与Dukes分期的增加有关。下前切除术后复发的患者更有可能出现非固定的、手术可矫正的病变,而不是腹会阴切除术后复发。与盆腔复发相关的最常见症状是疼痛,可能是会阴或放射到下肢。CT诊断1例局部复发直肠癌;影像学是评估局部肿瘤生长的范围和位置以及远处转移是否存在的第一步。最常见的位置是在吻合口附近和骶前区。除远处转移外,局部复发是决定预后和生存的最重要因素。如果能进行R0切除,5年生存率可达20-30%。局部或局部复发是指在完全切除肿瘤后肿瘤再次出现。对于直肠癌,邻近器官包括会阴、膀胱和阴道,LR失败包括会阴或盆腔病变。直肠癌局部复发患者行全盆腔切除,5年生存率为30-40%。对于无法切除的复发患者,化疗和放疗有助于提高生活质量,延长生存期。虽然放疗可以减少复发,但现在很明显,全肠系膜切除术是最有效的方式,其发生率低至5%。吻合口复发可以局部切除,长期生存的最佳方法是广泛的外科手术,需要整体切除邻近器官和盆腔结构,即所谓的复合切除术。术中放疗和近距离放疗,和/或术前放化疗可能在将来提供更好的结果。虽然放疗仍然是最常用的用于缓解症状的抗肿瘤方式,但手术切除仍然是结肠癌和直肠癌根治性治疗的主要方法。
{"title":"[Pelvic recurrence of rectal cancer: our experience].","authors":"N Di Bartolomeo,&nbsp;M R Balestra,&nbsp;G Liddo,&nbsp;P Innocenti","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Isolated recurrence of rectal carcinoma have been reported from 7% to 33% with a median of 15. Increasing recurrence is associated with increasing Dukes's stage. Patient who have recurrence after a low-anterior resection are more likely to present with non fixed, surgically correctable lesion versus recurrences after abdominoperineal resection. The most common symptom related to pelvic recurrence is pain, which may be perineal or radiate to the lower extremities. The diagnosis of a locally recurrent rectal cancer was obtained with CT; imaging is the first step to estimate the extent and location of the local tumor growth and the presence or absence of distant metastases. The most common location is at or around the anastomosis and the presacral region. Apart from distant metastases locoregional recurrence is the most important factor determining prognosis and survival. If an R0 resection can be performed, a 5-year survival rate of 20-30% can be achieved. Local or locoregional recurrence implies the reappearance of carcinoma after an intended complete removal of the tumor. For rectal cancer, the adjacent organs include the perineum, bladder and vagina, and LR failure includes perineal or pelvic lesions. Total pelvic exenteration is performed in patients with local recurrence of rectal cancer and a 5-year suvival rate of 30-40% was achieved. For patient with unresectable recurrence, chemotherapy and radiation contribute to a better quality of life and prolong survival. While radiotherapy may reduce recurrence, it is now apparent that total mesorectal excision is the most effective modality, with rates as low as 5%. The anastomotic recurrence that can be locally resected, the best approach for long-term survival is an extensive surgical procedure requiring en bloc removal of adjacent organs and pelvic structures so called composite resection. Intraoperative radiotherapy and brachytherapy, and/or preoperative chemoradiation may provide better results in future. While radioterapy remains the most common antineoplastic modality used for palliation of symptoms, surgical resection remains the mainstay of curative treatment for carcinoma of colon and rectum.</p>","PeriodicalId":84869,"journal":{"name":"I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]","volume":"4 3","pages":"S21-3"},"PeriodicalIF":0.0,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25821049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Gastrointestinal stromal tumors (GIST). Update and indications for treatment: our experience]. 胃肠道间质瘤(GIST)。最新情况和治疗适应症:我们的经验]。
G Bellanova, S Manfroni, A Serao, F Cavaliere, D Antonellis

The gastrointestinal stromal tumors (GISTs) represent 1% among bowel diseases. Their clinical history is unknown, and it seems to develop from muscolar or nervous tissue in the bowel wall. The grade of malignancy is directly correlate to the dimension of tumor and the number of mythosis for field. We report our experience in diagnosis and treatment.

胃肠道间质瘤(gist)占肠道疾病的1%。其临床病史不详,似乎起源于肠壁的肌肉或神经组织。恶性肿瘤的分级与肿瘤的大小和野区假丝的数量直接相关。我们报告我们的诊断和治疗经验。
{"title":"[Gastrointestinal stromal tumors (GIST). Update and indications for treatment: our experience].","authors":"G Bellanova,&nbsp;S Manfroni,&nbsp;A Serao,&nbsp;F Cavaliere,&nbsp;D Antonellis","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The gastrointestinal stromal tumors (GISTs) represent 1% among bowel diseases. Their clinical history is unknown, and it seems to develop from muscolar or nervous tissue in the bowel wall. The grade of malignancy is directly correlate to the dimension of tumor and the number of mythosis for field. We report our experience in diagnosis and treatment.</p>","PeriodicalId":84869,"journal":{"name":"I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]","volume":"4 3","pages":"S98"},"PeriodicalIF":0.0,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25821059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Intraperitoneal chemotherapy with oxaliplatin after complete cytoreduction for peritoneal carcinomatosis from colorectal carcinoma: preliminary experience]. 【奥沙利铂完全减细胞后腹腔化疗治疗大肠癌腹膜癌病:初步经验】。
G Mura, M Framarini, C Milandri, P Rosetti, A Vagliasindi, G Solfrini, P Mazza, G M Verdecchia

Colorectal cancer with peritoneal carcinomatosis is usually considered incurable. Intraperitoneal carcinomatosis accounts for 25-35% of recurrences of colorectal cancer. Studies demonstrate that peritoneal carcinomatosis is not necessarily a terminal condition with no options for treatment or cure. Encouraging results were obtained in many studies by cytoreductive surgery followed by hyperthermic intraoperative intraperitoneal chemotherapy (HIIC). Oxaliplatin is a new agent whose clinical use with intraperitoneal administration has been pioneered by Elias et al. Eight patients with peritoneal carcinomatosis (PC) of colo-rectal origin underwent complete cytoreductive surgery from March 2004 to January 2005. Six of them were submitted to HIIC with semi-closed technique; in one patient mitomycin C (2 mg/m2/l) was used for intraperitoneal perfusion at 41.5-42 degrees for 60 minutes; in five patients IPCH was carried out for 30 minutes at 41.5-42 degrees with intraperitoneal oxaliplatin (460 mg/m2). Patients received intravenous leucovorin (10 mg/m2) and 5-fluorouracil (400 mg/m2) just before HIIC to maximize the effect of oxaliplatin. Preliminary results are reported.

结直肠癌合并腹膜癌通常被认为是无法治愈的。腹腔内癌占结直肠癌复发率的25-35%。研究表明,腹膜癌并不一定是一种没有治疗或治愈选择的终末期疾病。在许多研究中,细胞减少手术后术中腹腔内热化疗(HIIC)获得了令人鼓舞的结果。奥沙利铂是一种新型药物,临床应用腹腔内给药是由Elias等人首创的。从2004年3月至2005年1月,我们对8例结直肠起源的腹膜癌(PC)进行了完全的细胞减少手术。其中6例采用半封闭技术提交HIIC;1例患者使用丝裂霉素C (2 mg/m2/l)在41.5 ~ 42度下腹腔灌注60分钟;5例患者在41.5-42度下腹腔注射奥沙利铂(460 mg/m2), IPCH持续30分钟。患者在HIIC前静脉注射亚叶酸素(10mg /m2)和5-氟尿嘧啶(400mg /m2)以最大化奥沙利铂的效果。初步结果报告。
{"title":"[Intraperitoneal chemotherapy with oxaliplatin after complete cytoreduction for peritoneal carcinomatosis from colorectal carcinoma: preliminary experience].","authors":"G Mura,&nbsp;M Framarini,&nbsp;C Milandri,&nbsp;P Rosetti,&nbsp;A Vagliasindi,&nbsp;G Solfrini,&nbsp;P Mazza,&nbsp;G M Verdecchia","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Colorectal cancer with peritoneal carcinomatosis is usually considered incurable. Intraperitoneal carcinomatosis accounts for 25-35% of recurrences of colorectal cancer. Studies demonstrate that peritoneal carcinomatosis is not necessarily a terminal condition with no options for treatment or cure. Encouraging results were obtained in many studies by cytoreductive surgery followed by hyperthermic intraoperative intraperitoneal chemotherapy (HIIC). Oxaliplatin is a new agent whose clinical use with intraperitoneal administration has been pioneered by Elias et al. Eight patients with peritoneal carcinomatosis (PC) of colo-rectal origin underwent complete cytoreductive surgery from March 2004 to January 2005. Six of them were submitted to HIIC with semi-closed technique; in one patient mitomycin C (2 mg/m2/l) was used for intraperitoneal perfusion at 41.5-42 degrees for 60 minutes; in five patients IPCH was carried out for 30 minutes at 41.5-42 degrees with intraperitoneal oxaliplatin (460 mg/m2). Patients received intravenous leucovorin (10 mg/m2) and 5-fluorouracil (400 mg/m2) just before HIIC to maximize the effect of oxaliplatin. Preliminary results are reported.</p>","PeriodicalId":84869,"journal":{"name":"I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]","volume":"4 3","pages":"S111-2"},"PeriodicalIF":0.0,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25821064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Strategic approach to immediate breast reconstruction with submuscular-fascial tissue expanders]. 肌下筋膜组织扩张器在乳房再造中的应用
P Persichetti, S Tenna, B Cagli, L Fortunato, C E Vitelli

Breast reconstruction can be accomplished with implants, autologous tissue or both. Thanks to the widespread of microsurgical techniques autologous tissue reconstruction has become a frequent option in many departments although it is mostly considered a second choice. The aim of this study was to review our experience covering the past five years in immediate breast reconstruction with tissue expanders. From January 2000 to January 2005 279 patients underwent immediate breast reconstruction with submuscular tissue expanders. Tissue expander was chosen according to dimension, shape and volume of the healthy breast. Operating time, early and late complications, interference with neo-adjuvant therapies as well as timing and surgical techniques of second-step reconstruction were also considered. No major complications occurred. Tissue expander, beyond proving itself a valid and safe option in immediate breast reconstruction, also decreased the psychological distress following a mastectomy.

乳房重建可以通过植入物、自体组织或两者同时完成。由于显微外科技术的广泛应用,自体组织重建已成为许多部门的常用选择,尽管它通常被认为是第二选择。本研究的目的是回顾我们在过去五年中使用组织扩张器进行乳房重建的经验。从2000年1月到2005年1月,279例患者接受了肌下组织扩张器的乳房重建。根据健康乳房的尺寸、形状和体积选择组织扩张器。考虑手术时间、早期和晚期并发症、对新辅助治疗的干扰以及第二步重建的时机和手术技术。无重大并发症发生。组织扩张器,除了证明自己是一个有效和安全的选择,在立即乳房重建,也减少了心理困扰后,乳房切除术。
{"title":"[Strategic approach to immediate breast reconstruction with submuscular-fascial tissue expanders].","authors":"P Persichetti,&nbsp;S Tenna,&nbsp;B Cagli,&nbsp;L Fortunato,&nbsp;C E Vitelli","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Breast reconstruction can be accomplished with implants, autologous tissue or both. Thanks to the widespread of microsurgical techniques autologous tissue reconstruction has become a frequent option in many departments although it is mostly considered a second choice. The aim of this study was to review our experience covering the past five years in immediate breast reconstruction with tissue expanders. From January 2000 to January 2005 279 patients underwent immediate breast reconstruction with submuscular tissue expanders. Tissue expander was chosen according to dimension, shape and volume of the healthy breast. Operating time, early and late complications, interference with neo-adjuvant therapies as well as timing and surgical techniques of second-step reconstruction were also considered. No major complications occurred. Tissue expander, beyond proving itself a valid and safe option in immediate breast reconstruction, also decreased the psychological distress following a mastectomy.</p>","PeriodicalId":84869,"journal":{"name":"I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]","volume":"4 3","pages":"S176"},"PeriodicalIF":0.0,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25821385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1